+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896193
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • EVER NEURO PHARMA GMBH
  • GlaxoSmithKline plc
  • MORE
Market Overview

The peptide therapeutics market is projected to grow with a CAGR of nearly 8.9% over the forecast period. The major factor attributing to the growth of the market is the growing incidence of metabolic disorders and cancers. According to the National Institute of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the increasing demand for efficient and low-cost drugs and rising investments in research and development of novel drugs boost market growth. However, the instability of peptides and stringent regulatory requirements for drug approval are the major factors restraining market growth.

Scope of the Report

As per the scope of the report peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less. This report is segmented by Marketing Type, by Application, by Route of Administration and by Geography.

Key Market Trends

Cancer Segment to Dominate the Market Over the Forecast Period
  • Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility.
  • The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.
  • According to the World Health Organization (WHO), cancer is the second prominent cause of death worldwide and is accountable for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.
  • Furthermore, rising awareness among patients and healthcare professionals regarding adverse effects of chemotherapy and radiation therapy is a major factor for growing focus towards alternative therapeutics such as peptide-based drugs.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutics products, increasing necessity for diagnostics in cancer and other diseases, and growing biotechnology industry. Increasing research and development expenditure by government and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical & pharmaceutical industry in this region is a major factor responsible for growth. In the North America region, the United States holds the largest market share due to factors such as an increasing number of research programs in the medical industry, along with a growing number of diseases in the country, which is anticipated to stimulate the demand in this region.

Competitive Landscape

The peptide therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Eli Lilly and Company; Pfizer, Inc.; Amgen, Inc.; Bristol-Myers Squibb; EVER NEURO PHARMA GMBH; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals Industries Ltd.; AstraZeneca PLC; GlaxoSmithKline plc; and Novo Nordisk A/S.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • EVER NEURO PHARMA GMBH
  • GlaxoSmithKline plc
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
4.2.2 Rising Investments in Research and Development of Novel Drugs
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Instability of Peptides
4.3.2 Stringent Regulatory Requirements for Drug Approval
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Marketing type
5.1.1 Generic
5.1.2 Branded
5.2 By Application
5.2.1 Gastrointestinal Disorders
5.2.2 Respiratory Disorders
5.2.3 Central Nervous System Disorders
5.2.4 Metabolic Disorders
5.2.5 Cardiovascular Diseases
5.2.6 Others
5.3 By Route of Administration
5.3.1 Parenteral
5.3.2 Oral
5.3.3 Pulmonary
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Amgen, Inc.
6.1.3 Pfizer, Inc.
6.1.4 Bristol-Myers Squibb
6.1.5 EVER NEURO PHARMA GMBH
6.1.6 Takeda Pharmaceutical Company Limited
6.1.7 Teva Pharmaceuticals Industries Ltd
6.1.8 AstraZeneca PLC
6.1.9 GlaxoSmithKline plc
6.1.10 Novo Nordisk A/S.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly and Company
  • Amgen, Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb
  • EVER NEURO PHARMA GMBH
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Novo Nordisk A/S.
Note: Product cover images may vary from those shown
Adroll
adroll